SMMT Stock Analysis: Buy, Sell, or Hold?
SMMT - Summit Therapeutics Inc. Common Stock
$19.38
0.46 (2.43%)
▲
5d:
+12.28%
30d:
+26.01%
90d:
+10.81%
HOLD
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 07, 2026
Get Alerted When SMMT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: SMMT is 11.1% above fair value ($17.44). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: SMMT is 11.1% above fair value ($17.44). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: SMMT is currently trading at $19.38, which is considered extended relative to its 30-day fair value range of $15.16 to $17.44.
Technical Outlook: Technically, SMMT is in a strong uptrend. The price is approaching resistance at $19.85. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SMMT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $29.09 (+50.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SMMT is in a strong uptrend. The price is approaching resistance at $19.85. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SMMT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $29.09 (+50.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$15.16 -
$17.44
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BEARISH: Price significantly overextended (+11.1% above fair value)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 50.1% below Wall St target ($29.09)
Fair Price Analysis
30-Day Fair Range
$15.16 -
$17.44
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$15.36
Resistance Level
$19.85
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-22.21
Wall Street Target
$29.09
(+50.1%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: April 02, 2026 6:54 PM ET
Data refreshes hourly during market hours. Next update: 7:54 PM
Data refreshes hourly during market hours. Next update: 7:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SMMT showing a specific setup today?
Insider Activity (6 Months)
3
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Mahkam Zanganeh
BUY
26680 shares
2025-10-21
Robert W Duggan
BUY
26680 shares
2025-10-21
Yu Xia
BUY
533617 shares
2025-10-21
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 61 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$43 | 65 BUY |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 58 HOLD |
